Lidocaine

Verify with FDA CVM →

316 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
316
Total Reports
92
Deaths Reported
2910.0%
Death Rate

Active Ingredients

Lidocaine

Administration Routes

UnknownIntravenousOtherSubcutaneousTopicalParenteralIntradermalPerineuralOralIntratesticular

Species Affected

Dog 190
Cat 103
Horse 6
Pig 5
Rabbit 3
Cattle 2
Guinea Pig 2
Mouse 1
Chinchilla 1
Other Reptiles 1

Most Affected Breeds

Domestic Shorthair 66
Retriever - Labrador 30
Domestic Longhair 17
Boxer (German Boxer) 14
Retriever - Golden 11
Terrier - Bull - American Pit 9
Crossbred Canine/dog 9
Shih Tzu 7
Dog (unknown) 6
Beagle 6

Most Reported Reactions

Death 57
Vomiting 41
Other abnormal test result NOS 34
Lethargy (see also Central nervous system depression in 'Neurological') 29
Behavioural disorder NOS 29
Tachycardia 28
Death by euthanasia 27
Diarrhoea 27
Lethargy (see also Central nervous system depression in Neurological) 25
Anorexia 24
Elevated alanine aminotransferase (ALT) 23
Lack of efficacy - NOS 23

Outcome Breakdown

Recovered/Normal
96 (29.8%)
Ongoing
84 (26.1%)
Died
63 (19.6%)
Outcome Unknown
50 (15.5%)
Euthanized
29 (9.0%)

Data Summary

Metric Value
Total adverse event reports 316
Reports involving death 92
Case-fatality rate (reported events) 2910.0%
Distinct species in reports 10
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Lidocaine Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 316 adverse event reports referencing Lidocaine, including 92 reports in which the animal died — a 2910.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Lidocaine. Reported administration routes include Unknown, Intravenous, Other, Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Lidocaine reports are Dog (190 reports), Cat (103 reports), Horse (6 reports), with Dog accounting for the largest share. Within those species, Domestic Shorthair (66), Retriever - Labrador (30), Domestic Longhair (17) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Lidocaine are Death (57), Vomiting (41), Other abnormal test result NOS (34), Lethargy (see also Central nervous system depression in 'Neurological') (29). Of the 322 reports with a coded outcome, Recovered/Normal is the leading category at 29.8%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Lidocaine.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial